Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

H. Stone, John; A. Merkel, Peter; Spiera, Robert; Seo, Philip; A. Langford, Carol; S. Hoffman, Gary; G. M. Kallenberg, Cees; William St. Clair, E.; Turkiewicz, Anthony; K. Tchao, Nadia; Webber, Lisa; Ding, Linna; P. Sejismundo, Lourdes; Mieras, Kathleen; Weitzenkamp, David; Iklé, David; Seyfert‐Margolis, Vicki; Mueller, Mark; Brunetta, Paul; B. Allen, Nancy; C. Fervenza, Fernando; Geetha, Duvuru; A. Keogh, Karina; Y. Kissin, Eugene; A. Monach, Paul; Peikert, Tobias; A. Stegeman, Coen; R. Ytterberg, Steven; Specks, Ulrich

doi:10.1056/nejmoa0909905

Public

Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis

Published in New England Journal of Medicine • Jul 14, 2010

Authors:

John H. Stone

Peter A. Merkel

Robert Spiera

Abstract

BACKGROUND: Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis for 40 years. Uncontrolled studies suggest that rituximab is effective and may be safer than a cyclophosphamide-based ...

Subject

Rituximab

Cyclophosphamide

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!